CytoReason secures $80m investment to expand disease modeling technologies

In a significant boost for the field of computational disease modeling, CytoReason announced an $80 million investment led by high-profile entities such as OurCrowd, NVIDIA Corporation (Nasdaq: NVDA), Pfizer Inc. (NYSE: PFE), and Thermo Fisher Scientific Inc. (NYSE: TMO). This new funding aims to enhance CytoReason’s development and application of predictive models across various medical indications and to support its global expansion, including the establishment of a new office in Cambridge, Massachusetts, later this year.

Reduced research and development (R&D) timelines and enhanced probability of technical and regulatory success are vital in today’s competitive life sciences landscape. CytoReason is at the forefront, providing key molecular-level insights through AI, which significantly aids therapeutic area leaders in making informed R&D decisions. This has been pivotal in boosting the phase 2 success rates and optimizing R&D portfolios for numerous companies.

Since expanding its partnership with Pfizer in 2022, CytoReason has notably increased its influence in the pharmaceutical sector. The company now boasts partnerships with three of the top ten global pharma companies and has broadened its disease model coverage to include central nervous system (CNS) related diseases. Additionally, the company’s scientific contributions continue to be recognized with frequent publications in esteemed journals like Nature, Cell, and Gut.

David Harel, Co-founder and CEO of CytoReason, emphasized the transformative potential of their work, “We are grateful for the infusion of new capital which will significantly bolster our efforts to pioneer the next generation of data-driven insights in pharma R&D.”

Contributing to this effort, Kimberly Powell, Vice President and General Manager, Healthcare at NVIDIA, highlighted the technological advancements, “CytoReason’s platforms have been supercharged with NVIDIA’s latest AI technologies, enhancing computational speeds by over tenfold.”

Mikael Dolsten, Chief Scientific Officer at Pfizer, also noted the broad implications of their collaboration, “The integration of AI and multiomics platforms is set to transform R&D, offering new pathways for drug development that benefit patients directly.”

Bhooshi De Silva from Thermo Fisher Scientific and Jon Medved, CEO of OurCrowd, both echoed the sentiments of growth and innovation powered by this strategic funding.

This influx of $80 million not only validates the success and potential of CytoReason’s technology but also sets a robust path for its future endeavors in enhancing the efficacy of R&D across the biopharma sector.